Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Bonum Therapeutics is raising $3,560,661.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Mulligan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bonum Therapeutics
At Good Therapeutics we are developing protein-based drugs with regulated, context-dependent activity. Our new drugs can sense their local environment and respond by changing from an inactive form to an active one. Unlike protease-activated therapeutics, the mechanism is reversible. The active form of the drug can change back to the inactive form when it is no longer in the presence of the activating signal. Our technology is based on allosteric control of protein activity a type of regulation that is widely found in nature but has yet to be applied to therapeutics.

To learn more about Bonum Therapeutics, visit http://goodtherapeutics.com/

Contact:
John Mulligan, Chief Executive Officer
206-888-8485
https://www.linkedin.com/in/john-mulligan-ph-d-5aa5a37/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved